Analysts think KALV stock price could increase by 226%
Dec 26, 2024, 12:25 PM
-1.71%
What does KALV do
KalVista Pharmaceuticals, based in Cambridge, Massachusetts, specializes in small molecule protease inhibitors for unmet medical needs, focusing on hereditary angioedema treatments like sebetralstat and Factor XIIa inhibitors. The company went public in April 2015 and employs 150 staff.
9 analysts think KALV stock price will increase by 226.03%. The current median analyst target is $28.56 compared to a current stock price of $8.76. The lowest analysts target is $18.18 and the highest analyst target is $40.95.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
